Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 14/20 | 0.65 |
| ▸ | F13A1 | P00488 | 4/20 | 0.59 |
| ▸ | TGM1 | P22735 | 4/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.59 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.59 |
| ▸ | THRA | P10827 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL439369 | 0.84 | TGM2 (0.79) | TGM2F13A1TGM1LMNATGM3 | |
| SCHEMBL21469043 | 0.83 | TGM2 (0.59) | TGM2F13A1TGM1LMNATGM3 | |
| SCHEMBL6358305 | 0.82 | TGM2 (0.71) | TGM2F13A1TGM1LMNATGM3 | |
| SCHEMBL1381808 | 0.81 | TGM2 (0.65) | TGM2F13A1TGM1LMNATGM3 | |
| SCHEMBL20322708 | 0.79 | HCAR3 (0.51) | TGM2F13A1TGM1LMNATGM3 | |
| SCHEMBL23328326 | 0.79 | TGM2 (0.61) | TGM2F13A1TGM1LMNATGM3 | |
| SCHEMBL38661653 | 0.79 | TGM2 (0.61) | TGM2F13A1TGM1LMNATGM3 | |
| SCHEMBL2723385 | 0.79 | TGM2 (0.61) | TGM2F13A1TGM1LMNATGM3 | |
| SCHEMBL2722982 | 0.79 | TGM2 (0.61) | TGM2F13A1TGM1LMNATGM3 | |
| SCHEMBL648950 | 0.79 | TGM2 (1.00) | TGM2F13A1TGM1LMNATGM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210403460-A1 | INHIBITORS OF MUTANT ISOCITRATE DEHYDROGENASES AND COMPOSITIONS AND METHODS THEREOF | ISOCURE BIOSCIENCES INC (US) | 2021-12-30 | — | — | US | disclosed |
| US-11149032-B2 | Inhibitors of mutant isocitrate dehydrogenases and compositions and methods thereof | ISOCURE BIOSCIENCES INC. (US) | 2021-10-19 | — | — | US | disclosed |
| US-20200071309-A1 | INHIBITORS OF MUTANT ISOCITRATE DEHYDROGENASES AND COMPOSITIONS AND METHODS THEREOF | ISOCURE BIOSCIENCES INC (US) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210403460-A1 | INHIBITORS OF MUTANT ISOCITRATE DEHYDROGENASES AND COMPOSITIONS AND METHODS THEREOF | IDH1, IDH2, IDH3A | TGM2 525/4885F13A1 3752/4885TGM1 960/4885 |
| US-11149032-B2 | Inhibitors of mutant isocitrate dehydrogenases and compositions and methods thereof | IDH1, IDH2, IDH3A | TGM2 525/4885F13A1 3752/4885TGM1 960/4885 |
| US-20200071309-A1 | INHIBITORS OF MUTANT ISOCITRATE DEHYDROGENASES AND COMPOSITIONS AND METHODS THEREOF | IDH1, IDH2, IDH3A | TGM2 525/4885F13A1 3752/4885TGM1 960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.